Clinical trials: Human Papillomavirus Vaccines
Human Papillomavirus
KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)
The Global Alliance to Immunize Against AIDS Vaccine Foundation (GAIA Vaccine Foundation or GAIA VF) proposes to carry out a Knowledge, Attitudes, and Practices (KAP) study in conjunction with a Willingness To Participate (WTP)…
- Trial name
- HPV (NCT01314404)
- Where
- 2 sites in Mali
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Global Alliance to Immunize Against AIDS Vaccine Foundation
Papillomavirus Infections
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
The primary objective of this study is the estimation of the human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52 and 58 seroconversion at 1 month post last dose (Month 7) following 3 doses and 2 doses of the 9-valent human…
- Trial name
- NCT04772534
- Testing
- 9vHPV vaccine
- Where
- 12 sites in Japan
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Completion of Three Dose Series of HPV, Improvement in Vaccine Intervals Between HPV Doses
The Efficacy of Reminders to Complete HPV Series
The human papillomavirus (HPV) vaccine is routinely recommended for both adolescent girls and boys starting at age 11, although it can be offered as young as 9 years of age.
- Trial name
- ICHAT (NCT01731496)
- Testing
- Telephone reminder, Text Message reminder
- Where
- 3 sites in United States
- Volunteers
- 749 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Cervical Cancer, Genital Warts
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean…
- Trial name
- ADS (NCT02280642)
- Testing
- Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late
- Where
- 3 sites in United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- Duke University
Health Education
The Effects of Health Education About Human Papilloma Virus and Cervical Cancer Prevention on Knowledge, Attitudes, Beliefs and Behaviors
Aim: To determine the effects of health education about Human Papilloma Virus infection and cervical cancer prevention on knowledge, attitudes, beliefs and behaviors of adolescent girls and their mothers.
- Trial name
- NCT04113902
- Testing
- Health Education
- Where
- Turkey (Türkiye)
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Randomized, 2-arm observational study. The 2 arms (randomized at the level of health care provider) will be: 1. usual practice; 2.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02558803
- Testing
- Simple Reminder
- Where
- 5 sites in United States
- Volunteers
- 1,305 people
- Sponsor
- Regenstrief Institute, Inc.
Cervical Intraepithelial Neoplasia, Cervical Cancer
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
This study is to evaluate lot-lot consistency of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) .
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT05426148
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Human Papillomavirus Infection
A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age.
- Trial name
- NCT01984697
- Testing
- V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
- Volunteers
- 1,518 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Head and Neck, Oropharynx
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Background: Throat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy
- Trial name
- NCT06223568
- Testing
- Docetaxel, Cisplatin, PRGN-2009
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico
In September 2009 the National Vaccination Council approved the policy for anti-HPV vaccination in 9-year-old girls with an extended scheme of 0, 6, and 60 months, under the following justification: Antibody induction due to the…
- Trial name
- NCT01717118
- Testing
- Bivalent Vaccines, Tetravalent Vaccine
- Where
- Mexico
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
Human Papillomavirus, Cervix Cancer
Prevention of HPV in the School Health Service
The last ten years sexually transmitted infections (STI) have substantially increased among adolescents. STI can lead to individual suffering and have a negative effect on the future reproductive health and also increase the need…
- Trial name
- NCT02280967
- Testing
- Education about HPV by school nurse
- Where
- Sweden
- Volunteers
- 832 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Cervical Cancer Stage IVB
A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The study medications were used as follows: 1 cycle every 21 days (3 weeks) of the following regimen. Test drug: QL1706, HPV 9-valent vaccine QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on Day 1 of each…
- Trial name
- QL1706 (NCT06882447)
- Testing
- Trial drug: QL1706, HPV 9-valent vaccine
- Volunteers
- 35 people
- Sponsor
- Northern Jiangsu People's Hospital
Cancer Survivor, Prevention of Human Papillomavirus Infection
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2)…
- Trial name
- NCT01492582
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration
- Where
- 5 sites in United States
- Volunteers
- 1,499 people
- Sponsor
- University of Alabama at Birmingham
Infections, Papillomavirus
Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00196924
- Testing
- HPV-16/18 L1/AS04
- Where
- 61 sites in Australia, Colombia and 10 more
- Volunteers
- 2,067 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV
Multi-level School-based Intervention to Improve HPV Vaccine Uptake and Completion in South Africa
Human Papillomavirus (HPV) is the most common sexually transmitted infection globally, and is causally linked to cervical, anogenital, and oropharyngeal cancers.
- Trial name
- NCT05919901
- Testing
- HPV Vaccine Communication Strategy
- Where
- South Africa
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Immunization, Vaccination
The STOP-HPV Trial 1: Communication Intervention
Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates.
- Trial name
- STOP-HPV (NCT03599557)
- Testing
- STOP-HPV communication intervention
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Cervical Cancer, Condylomata Acuminata
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females…
- Trial name
- NCT06197802
- Testing
- Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9
- Where
- China
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Xiamen University
HPV Vaccine Attitudes, HPV Vaccine Intention
HPV Vaccine Acceptability Among Young Men Who Have Sex With Men
The FDA has recently approved Gardasil for the prevention of anal cancer in people aged 9-26. Men who have sex with men (MSM) have disproportionately high rates of anal cancer and could benefit greatly from vaccination.
- Trial name
- NCT01535794
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Indiana University
Human Papillomavirus Infection
Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004
This long-term extension study evaluates the persistence of neutralizing antibody responses to a bivalent human papillomavirus vaccine in females who previously participated in study 311-HPV-1004 (NCT02740777).
- Trial name
- NCT07820241
- Testing
- Bivalent Human Papillomavirus Vaccine (Types 16 and 18, Pichia pastoris)
- Where
- 2 sites in China
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
- Trial name
- NCT00054041
- Testing
- HspE7, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)